跳至主要內容
Launxp_Logo
  • Home
  • News
  • About
  • R&D Projects
    • Overview
    • LXPA1788
    • LXPA1988
    • LXPA5948
    • LXPB5101
    • LXPB5268
    • Virus-like Particles
  • Investors
    • Material Information
    • Corporate Governance
    • Shareholder’s Area
    • Financial Information
  • Contact
  • English
    • 繁中
    • 简中
選單
  • Home
  • News
  • About
  • R&D Projects
    • Overview
    • LXPA1788
    • LXPA1988
    • LXPA5948
    • LXPB5101
    • LXPB5268
    • Virus-like Particles
  • Investors
    • Material Information
    • Corporate Governance
    • Shareholder’s Area
    • Financial Information
  • Contact
  • English
    • 繁中
    • 简中

News & Events

朗齊生醫子公司與Apollomics簽合作協議 獲亞洲區APL-101開發與商業化權利

Read More ⟶
03/31/2025
Biotech

LXPB5268臨床試驗成果階段性發表獲獎

Read More ⟶
10/26/2024
Biotech

國衛院授權朗齊多靶點抗癌藥物LXPA1788獲台北生技金獎肯定

Read More ⟶
09/24/2024
Event

We participated in the American Society of Clinical Oncology (ASCO) annual meeting

Read More ⟶
04/10/2024
Event

INTERPHEX Week Tokyo

Read More ⟶
07/07/2023
Event

2023 InnoVEX in Taipei

Read More ⟶
06/02/2023
Launxp Logo

Developing new cancer drugs. Improving patients' life.

Linkedin
Links
  • Home
  • News
  • About
  • R&D Projects
  • Contact
  • Home
  • News
  • About
  • R&D Projects
  • Contact
Investors
  • Material Information
  • Corporate Governance
  • Shareholder’s Area
  • Financial Information
  • Material Information
  • Corporate Governance
  • Shareholder’s Area
  • Financial Information
Get In Touch

Room B1, 10F., No. 51
Section 2, Gongyi Rd.
Nantun Dist. 408
Taichung City, Taiwan 

  • lxp@launxp.com
  • 04-2320-5691

© LaunXP Biomedical Co., Ltd.

Design: UThink Med Visuals